Katri Kaukinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katri Kaukinen has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Kalle Kurppa
Tampere University
21 shared publications - Katri Lindfors
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
18 shared publications - Heini Huhtala
Faculty of Social Sciences University of Tampere Tampere Finland
16 shared publications - Päivi Saavalainen
Folkhälsan Research Center, Biomedicum, Helsinki, Finland; Immunomics Research Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland
12 shared publications - Teea Salmi
Faculty of Medicine and Health Technology Tampere University Tampere Finland
9 shared publications - Laura Kivelä
Celiac Disease Research Center Tampere University Tampere Finland
7 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Connecting Skin and Gut in Dermatitis Herpetiformis: Insights from Gluten Challenge Transcriptomics
Dermatitis herpetiformis (DH) is a dietary gluten -induced autoimmune blistering skin disease. It is hypothesized to be initiated by a small intestinal mucosal immune response. Gluten-free diet (GFD) is the primary treatment for DHdermatitis herpetiformis and effectively resolves skin lesions. Previous studies show that after gluten reintroduction, peripheral cell responses are detectable already in six6 days, and most patients relapse clinically within months. The relapse presentation may differ between patients, with some experiencing both rash and small intestinal mucosal damage and some only one of these. Here, RNA transcriptomics were utilized to characterize temporal systemic and small intestinal mucosal responses to gluten in DH,dermatitis herpetiformis and to identify transcriptomic profiles specific for rash or villous atrophy as relapse presentations. The cohort consisted of 19 DHdermatitis herpetiformis patients on GFDgluten-free diet who underwent a gluten challenge. Gluten challenge elicited pronounced gene expression changes related to inflammation in the small intestine. In patients relapsing with rash, DOCK8 expression was significantly upregulated, while IL10RB was downregulated at end of follow-up. These patients also had significantly increased frequency of intraepithelial lymphocytes. Our findings show that prolonged gluten exposure alters duodenal transcriptomic profiles considerably. Moreover, patterns related to rash could be detected and present interesting candidates for future studies.
- 9 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessConnecting Skin and Gut in Dermatitis Herpetiformis: Insights from Gluten Challenge Transcriptomics
Dermatitis herpetiformis (DH) is a dietary gluten -induced autoimmune blistering skin disease. It is hypothesized to be initiated by a small intestinal mucosal immune response. Gluten-free diet (GFD) is the primary treatment for DHdermatitis herpetiformis and effectively resolves skin lesions. Previous studies show that after gluten reintroduction, peripheral cell responses are detectable already in six6 days, and most patients relapse clinically within months. The relapse presentation may differ between patients, with some experiencing both rash and small intestinal mucosal damage and some only one of these. Here, RNA transcriptomics were utilized to characterize temporal systemic and small intestinal mucosal responses to gluten in DH,dermatitis herpetiformis and to identify transcriptomic profiles specific for rash or villous atrophy as relapse presentations. The cohort consisted of 19 DHdermatitis herpetiformis patients on GFDgluten-free diet who underwent a gluten challenge. Gluten challenge elicited pronounced gene expression changes related to inflammation in the small intestine. In patients relapsing with rash, DOCK8 expression was significantly upregulated, while IL10RB was downregulated at end of follow-up. These patients also had significantly increased frequency of intraepithelial lymphocytes. Our findings show that prolonged gluten exposure alters duodenal transcriptomic profiles considerably. Moreover, patterns related to rash could be detected and present interesting candidates for future studies.
- Open Access
- 7 September 2026
- Published by SAGE Publications in Nutrition and Health
Other special diets in addition to gluten-free diet are common among youth with celiac disease, but are not associated with overall well-being or treatment success
Background: Various special diets have become increasingly common. However, their prevalence and significance in patients with celiac disease (CeD) who already adhere to a gluten-free diet (GFD) are unclear. Aim: We studied the abovementioned aspects in youth with CeD and controls. Methods: 210 patients and 212 controls, all adolescents and young adults with comparable age 16–30 years, completed an anonymous survey. Variables were compared between CeD patients with and without additional dietary restriction. Results: Overall, 53% of CeD patients and 81% of controls were students and 41% vs. 18% working. One-third of patients and controls reported adhering to special diets, particularly a vegetarian/vegan diet (9%/14%), an allergy diet (8%/7%), and a diet for irritable bowel syndrome (7%/8%). Patients with and without an additional diet besides a GFD were comparable in terms of sex, current age, age at diagnosis, body mass index, student/employment status, physical activity, and consumption of alcohol and tobacco. However, those following only a GFD reported fewer gastrointestinal symptoms at diagnosis (58% vs. 75%, p = 0.021) and fewer challenges with school and workplace meals (27% vs. 39%, p = 0.020) than those with another restrictive diet. Altogether 11% reported difficulties combining GFD and other diet, but there were no differences in adherence (91% vs. 93%, p = 0.705), persistent symptoms, health concerns, or well-being. Conclusion: One-third of CeD patients followed additional special diets, similar to the controls. While additional restrictions may not necessarily compromise well-being or treatment success, including GFD adherence and symptom resolution, they posed challenges that underline the need to consider them in CeD management.
- 7 September 2026
- Published by SAGE Publications in Nutrition and Health
Open AccessOther special diets in addition to gluten-free diet are common among youth with celiac disease, but are not associated with overall well-being or treatment success
Background: Various special diets have become increasingly common. However, their prevalence and significance in patients with celiac disease (CeD) who already adhere to a gluten-free diet (GFD) are unclear. Aim: We studied the abovementioned aspects in youth with CeD and controls. Methods: 210 patients and 212 controls, all adolescents and young adults with comparable age 16–30 years, completed an anonymous survey. Variables were compared between CeD patients with and without additional dietary restriction. Results: Overall, 53% of CeD patients and 81% of controls were students and 41% vs. 18% working. One-third of patients and controls reported adhering to special diets, particularly a vegetarian/vegan diet (9%/14%), an allergy diet (8%/7%), and a diet for irritable bowel syndrome (7%/8%). Patients with and without an additional diet besides a GFD were comparable in terms of sex, current age, age at diagnosis, body mass index, student/employment status, physical activity, and consumption of alcohol and tobacco. However, those following only a GFD reported fewer gastrointestinal symptoms at diagnosis (58% vs. 75%, p = 0.021) and fewer challenges with school and workplace meals (27% vs. 39%, p = 0.020) than those with another restrictive diet. Altogether 11% reported difficulties combining GFD and other diet, but there were no differences in adherence (91% vs. 93%, p = 0.705), persistent symptoms, health concerns, or well-being. Conclusion: One-third of CeD patients followed additional special diets, similar to the controls. While additional restrictions may not necessarily compromise well-being or treatment success, including GFD adherence and symptom resolution, they posed challenges that underline the need to consider them in CeD management.
- Open Access
- 10 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (9) , 1248-1259
Screen‐Detected Coeliac Disease in a Nationally Representative Cohort: Health Indicators, Long‐Term Outcomes and Mortality
Background: Population‐based screening for coeliac disease could reduce underdiagnosis, but benefits and harms remain debated. Aim: We studied health outcomes in screen‐detected coeliac disease patients at diagnosis and following a long‐term gluten‐free diet. Methods: Data were collected from Health 2000 and 2011 studies representing the Finnish population. Coeliac disease was screened in 6339 individuals by transglutaminase and endomysial antibodies, with dual seropositivity as the diagnostic criterion, histologically validated in this cohort. Survey‐weighted analyses enabled population‐level results. The follow‐up cohort comprised those participating in both time points. Mortality was assessed between 2000 and 2017. Results: At screening, 92 (1.5%) undiagnosed coeliac disease patients and 6216 non‐coeliac controls were identified. Patients were less often smokers (11% vs. 22%, p = 0.014), more often had a history of pre‐eclampsia (13% vs. 5%, p = 0.037) and anaemia (14% vs. 6%, p = 0.012), and lower ferritin (29 vs. 68 ng/mL, p < 0.001), with an altered lipid profile including lower total cholesterol, LDL‐C, and ApoB but higher atherogenic ratios. At 11‐year follow‐up, mental health, quality of life, and cardiometabolic markers were comparable between treated coeliac disease patients ( n = 50) and non‐coeliac controls ( n = 3226). Mortality did not differ after adjustment for age and sex (HR 0.77, 95% CI 0.45–1.33). Conclusions: Nationally screened adults with undiagnosed coeliac disease showed iron deficiency and anaemia. Long‐term dietary treatment did not adversely affect quality of life or cardiometabolic health and may prevent complications. Furthermore, mortality was comparable to the general population. The results suggest a favourable benefit‐harm balance for population‐based screening.
- 10 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (9) , 1248-1259
Open AccessScreen‐Detected Coeliac Disease in a Nationally Representative Cohort: Health Indicators, Long‐Term Outcomes and Mortality
Background: Population‐based screening for coeliac disease could reduce underdiagnosis, but benefits and harms remain debated. Aim: We studied health outcomes in screen‐detected coeliac disease patients at diagnosis and following a long‐term gluten‐free diet. Methods: Data were collected from Health 2000 and 2011 studies representing the Finnish population. Coeliac disease was screened in 6339 individuals by transglutaminase and endomysial antibodies, with dual seropositivity as the diagnostic criterion, histologically validated in this cohort. Survey‐weighted analyses enabled population‐level results. The follow‐up cohort comprised those participating in both time points. Mortality was assessed between 2000 and 2017. Results: At screening, 92 (1.5%) undiagnosed coeliac disease patients and 6216 non‐coeliac controls were identified. Patients were less often smokers (11% vs. 22%, p = 0.014), more often had a history of pre‐eclampsia (13% vs. 5%, p = 0.037) and anaemia (14% vs. 6%, p = 0.012), and lower ferritin (29 vs. 68 ng/mL, p < 0.001), with an altered lipid profile including lower total cholesterol, LDL‐C, and ApoB but higher atherogenic ratios. At 11‐year follow‐up, mental health, quality of life, and cardiometabolic markers were comparable between treated coeliac disease patients ( n = 50) and non‐coeliac controls ( n = 3226). Mortality did not differ after adjustment for age and sex (HR 0.77, 95% CI 0.45–1.33). Conclusions: Nationally screened adults with undiagnosed coeliac disease showed iron deficiency and anaemia. Long‐term dietary treatment did not adversely affect quality of life or cardiometabolic health and may prevent complications. Furthermore, mortality was comparable to the general population. The results suggest a favourable benefit‐harm balance for population‐based screening.
- Open Access
Planar, organoid-independent iPSC-derived small intestinal epithelium from celiac disease patient for studying cytokine-induced changes
Background & Aims: Celiac disease is a wheat-induced immune-mediated enteropathy characterized by cytokine, especially IFNγ upregulation. Intestinal organoid models for adult stem cell–based celiac disease exist, but planar iPSC based small intestinal epithelial models derived from celiac disease patients that would allow direct assessment from both sides of the epithelium have been lacking. We aimed to bridge this gap by setting up a two-dimensional in vitro model based on small intestinal epithelial cells derived from iPSC from celiac disease patient. Methods: IPSCs from celiac disease patient and control patient were directly differentiated into small intestinal epithelium on Transwell inserts without intermediate organoid phase or replating. Model maturity and celiac disease specific cytokine responses were analysed using immunofluorescence, transcriptomic profiling, and LDH cytotoxicity assay. Results: Two-dimensionally cultured c eliac disease derived line and control patient derived iPSCs matured similarly towards intestinal epithelium which expressed enterocyte specific PEPT1 and EpCAM. To the cytokine stimuli, celiac and healthy iPSC-SIECs responded by increasing the expression IRF1, ICAM1 and IDO1, and several other known cytokine responsive genes. Conclusions: These findings suggest that the 2D iPSC celiac disease small intestinal epithelium model represent an appropriate platform for studying inflammation-associated enteropathies, such as celiac disease.
Open AccessPlanar, organoid-independent iPSC-derived small intestinal epithelium from celiac disease patient for studying cytokine-induced changes
Background & Aims: Celiac disease is a wheat-induced immune-mediated enteropathy characterized by cytokine, especially IFNγ upregulation. Intestinal organoid models for adult stem cell–based celiac disease exist, but planar iPSC based small intestinal epithelial models derived from celiac disease patients that would allow direct assessment from both sides of the epithelium have been lacking. We aimed to bridge this gap by setting up a two-dimensional in vitro model based on small intestinal epithelial cells derived from iPSC from celiac disease patient. Methods: IPSCs from celiac disease patient and control patient were directly differentiated into small intestinal epithelium on Transwell inserts without intermediate organoid phase or replating. Model maturity and celiac disease specific cytokine responses were analysed using immunofluorescence, transcriptomic profiling, and LDH cytotoxicity assay. Results: Two-dimensionally cultured c eliac disease derived line and control patient derived iPSCs matured similarly towards intestinal epithelium which expressed enterocyte specific PEPT1 and EpCAM. To the cytokine stimuli, celiac and healthy iPSC-SIECs responded by increasing the expression IRF1, ICAM1 and IDO1, and several other known cytokine responsive genes. Conclusions: These findings suggest that the 2D iPSC celiac disease small intestinal epithelium model represent an appropriate platform for studying inflammation-associated enteropathies, such as celiac disease.
- Open Access
- 2 December 2025
- Published by S. Karger AG in Digestion
- p. 1-10
Characteristics and Long-Term Prognosis of Celiac Disease: Comparisons between Patients Diagnosed either in Childhood or Adulthood
Introduction: It is plausible but not yet proven that early celiac disease diagnosis prevents long-term complications of untreated disease. Our aim was to compare phenotype and health outcomes in currently adult celiac disease patients diagnosed either in childhood (<18 years) or adulthood. Methods: Data on 1,059 patients were collected from medical records at diagnosis and with questionnaires and structured interviews after long-term follow-up. Associations between timing of diagnosis and long-term health were studied with regression models. Results: Patients diagnosed in childhood (n = 239) were more often males (32% vs. 23%, p = 0.004), currently younger (27 vs. 54 years, p < 0.001), more often screen-detected (20% vs. 14%, p < 0.001), and reported lower adherence to gluten-free diet in adulthood (92% vs. 97%, p < 0.001) than those diagnosed in adulthood (n = 820). After adjusting for clinico-demographic variables and dietary adherence, patients diagnosed in childhood had fewer miscarriages (odds ratio 0.41 [95% confidence interval: 0.21–0.80]) but more allergies (1.75 [1.11–2.76]), dermatological diseases excluding dermatitis herpetiformis (1.99 [1.11–3.58]), asthma (2.28 [1.16–4.48]), and depression (2.84 [1.24–6.50]) in adulthood. The groups were comparable in other comorbidities including type 1 diabetes and autoimmune thyroidal diseases, persistent symptoms, and quality of life. Conclusion: Diagnosis in childhood compared to adulthood was associated with disease phenotype and its effects on long-term comorbidities are complex.
- 2 December 2025
- Published by S. Karger AG in Digestion
- p. 1-10
Open AccessCharacteristics and Long-Term Prognosis of Celiac Disease: Comparisons between Patients Diagnosed either in Childhood or Adulthood
Introduction: It is plausible but not yet proven that early celiac disease diagnosis prevents long-term complications of untreated disease. Our aim was to compare phenotype and health outcomes in currently adult celiac disease patients diagnosed either in childhood (<18 years) or adulthood. Methods: Data on 1,059 patients were collected from medical records at diagnosis and with questionnaires and structured interviews after long-term follow-up. Associations between timing of diagnosis and long-term health were studied with regression models. Results: Patients diagnosed in childhood (n = 239) were more often males (32% vs. 23%, p = 0.004), currently younger (27 vs. 54 years, p < 0.001), more often screen-detected (20% vs. 14%, p < 0.001), and reported lower adherence to gluten-free diet in adulthood (92% vs. 97%, p < 0.001) than those diagnosed in adulthood (n = 820). After adjusting for clinico-demographic variables and dietary adherence, patients diagnosed in childhood had fewer miscarriages (odds ratio 0.41 [95% confidence interval: 0.21–0.80]) but more allergies (1.75 [1.11–2.76]), dermatological diseases excluding dermatitis herpetiformis (1.99 [1.11–3.58]), asthma (2.28 [1.16–4.48]), and depression (2.84 [1.24–6.50]) in adulthood. The groups were comparable in other comorbidities including type 1 diabetes and autoimmune thyroidal diseases, persistent symptoms, and quality of life. Conclusion: Diagnosis in childhood compared to adulthood was associated with disease phenotype and its effects on long-term comorbidities are complex.
- Open Access
- 17 October 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1133-1136.e4
Dermal IgA Is Rare in Celiac Disease and Relatives and Lacks Dermatitis Herpetiformis-Type Colocalization with Transglutaminase 3
- 17 October 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1133-1136.e4
Open AccessDermal IgA Is Rare in Celiac Disease and Relatives and Lacks Dermatitis Herpetiformis-Type Colocalization with Transglutaminase 3
- Open Access
- 26 April 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (6) , 1209-1215
Persistent antibody positivity and gastrointestinal symptoms predicted progression of potential celiac disease to celiac disease
- 26 April 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (6) , 1209-1215
Open AccessPersistent antibody positivity and gastrointestinal symptoms predicted progression of potential celiac disease to celiac disease
- 12 December 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 135, 153-155
Risk for hospital-treated infections in dermatitis herpetiformis and coeliac disease
- 12 December 2024
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 135, 153-155
Risk for hospital-treated infections in dermatitis herpetiformis and coeliac disease
- Open Access
- 29 June 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33 (2) , 170-176
Impact of Cigarette Smoking on Clinical Presentation and Treatment Response in Coeliac Disease
Background and Aims: The environmental factors, apart from gluten ingestion predisposing to coeliac disease are poorly known. Smoking is associated with many immune-mediated diseases, but research on coeliac disease is scarce. This study aims to investigate how smoking affects the clinical presentation, presence of comorbidities and response to gluten-free diet in coeliac disease. Methods: Altogether 815 adults with coeliac disease participated in a nationwide cross-sectional study. Participants were interviewed and smoking habits (never, former, or current smoker), clinical presentation of coeliac disease and presence of comorbidities were elicited. Serology and severity of small bowel mucosal lesions at diagnosis were gathered from the participants’ medical records and follow-up serology was measured. Gastrointestinal symptoms and psychological well-being were assessed using validated questionnaires. Results: Current smokers were more often male and were diagnosed at younger ages than never or former smokers. There were no differences between the groups in clinical presentation, severity of symptoms or mucosal lesions at diagnosis or in dietary compliance and clinical, serological, and histological recovery. Musculoskeletal disorders, particularly osteoporosis and osteopenia, were more common in never smokers than in other groups (14.5% vs. 5.1% and 4.1%, p<0.001), and cardiovascular disorders were diagnosed more often in former smokers (36.2% vs. 23.5% and 21.9%, p=0.003). Conclusions: Smoking does not seem to have an impact on the clinical presentation, severity of symptoms or mucosal damage in coeliac disease. Histological and clinical recovery as well as seroconversion on gluten-free diet are not affected by smoking status.
- 29 June 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33 (2) , 170-176
Open AccessImpact of Cigarette Smoking on Clinical Presentation and Treatment Response in Coeliac Disease
Background and Aims: The environmental factors, apart from gluten ingestion predisposing to coeliac disease are poorly known. Smoking is associated with many immune-mediated diseases, but research on coeliac disease is scarce. This study aims to investigate how smoking affects the clinical presentation, presence of comorbidities and response to gluten-free diet in coeliac disease. Methods: Altogether 815 adults with coeliac disease participated in a nationwide cross-sectional study. Participants were interviewed and smoking habits (never, former, or current smoker), clinical presentation of coeliac disease and presence of comorbidities were elicited. Serology and severity of small bowel mucosal lesions at diagnosis were gathered from the participants’ medical records and follow-up serology was measured. Gastrointestinal symptoms and psychological well-being were assessed using validated questionnaires. Results: Current smokers were more often male and were diagnosed at younger ages than never or former smokers. There were no differences between the groups in clinical presentation, severity of symptoms or mucosal lesions at diagnosis or in dietary compliance and clinical, serological, and histological recovery. Musculoskeletal disorders, particularly osteoporosis and osteopenia, were more common in never smokers than in other groups (14.5% vs. 5.1% and 4.1%, p<0.001), and cardiovascular disorders were diagnosed more often in former smokers (36.2% vs. 23.5% and 21.9%, p=0.003). Conclusions: Smoking does not seem to have an impact on the clinical presentation, severity of symptoms or mucosal damage in coeliac disease. Histological and clinical recovery as well as seroconversion on gluten-free diet are not affected by smoking status.
- Open Access
- 9 November 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 372-379
Trends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study
Summary: Background: The prevalence of coeliac disease doubled in Finland from 1980 to 2000.Aims: To investigate whether this increase is continuing and if there are specific patient‐related factors predicting the development of coeliac disease at a population level.Methods: We elicited comprehensive health data in the nationwide Health 2000 and Health 2011 surveys. Serum samples were taken for the measurement of tissue transglutaminase antibodies (TGA); subjects who were seropositive were tested for endomysial antibodies (EmA). Coeliac disease was defined either as a reported diagnosis or as positive TGA and EmA. The surveys comprised, respectively, 6379 and 4056 individuals, forming representative samples for 2,946,057 and 2,079,438 Finnish adults. Altogether 3254 individuals participating in both surveys comprised a prospective follow‐up cohort.Results: Prevalence of coeliac disease was 2.12% in 2000 and 2.40% in 2011 (p = 0.156). In the prospective cohort, 16 out of the 3254 (0.49%) subjects developed coeliac disease during follow‐up from 2000 to 2011, with an annual incidence rate of 45 per 100,000 persons. Positive TGA without EmA (OR: 133, 95% CI: 30.3–584), TGA values in the upper normal range (51.1, 16.0–163), and after adjusting for TGA, previous autoimmune co‐morbidity (8.39, 4.98–35.9) in 2000 increased the likelihood of subsequent coeliac disease.Conclusions: The nationwide prevalence of coeliac disease kept on rising from 2.12% in 2000 to 2.40% in 2011 in Finland. Positive TGA without EmA, TGA titres in the upper normal range and a pre‐existing autoimmune disease predisposed to coeliac disease during the 10‐year follow‐up.
- 9 November 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 372-379
Open AccessTrends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study
Summary: Background: The prevalence of coeliac disease doubled in Finland from 1980 to 2000.Aims: To investigate whether this increase is continuing and if there are specific patient‐related factors predicting the development of coeliac disease at a population level.Methods: We elicited comprehensive health data in the nationwide Health 2000 and Health 2011 surveys. Serum samples were taken for the measurement of tissue transglutaminase antibodies (TGA); subjects who were seropositive were tested for endomysial antibodies (EmA). Coeliac disease was defined either as a reported diagnosis or as positive TGA and EmA. The surveys comprised, respectively, 6379 and 4056 individuals, forming representative samples for 2,946,057 and 2,079,438 Finnish adults. Altogether 3254 individuals participating in both surveys comprised a prospective follow‐up cohort.Results: Prevalence of coeliac disease was 2.12% in 2000 and 2.40% in 2011 (p = 0.156). In the prospective cohort, 16 out of the 3254 (0.49%) subjects developed coeliac disease during follow‐up from 2000 to 2011, with an annual incidence rate of 45 per 100,000 persons. Positive TGA without EmA (OR: 133, 95% CI: 30.3–584), TGA values in the upper normal range (51.1, 16.0–163), and after adjusting for TGA, previous autoimmune co‐morbidity (8.39, 4.98–35.9) in 2000 increased the likelihood of subsequent coeliac disease.Conclusions: The nationwide prevalence of coeliac disease kept on rising from 2.12% in 2000 to 2.40% in 2011 in Finland. Positive TGA without EmA, TGA titres in the upper normal range and a pre‐existing autoimmune disease predisposed to coeliac disease during the 10‐year follow‐up.